Johnson & Johnson Advances Leadership in Rheumatic Disease Innovation With 43 Abstracts at ACR 2024
November 08, 2024
November 08, 2024
NEW BRUNSWICK, New Jersey, Nov. 8 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
New data for investigational nipocalimab in Sjogren's Disease (SjD) and new research on the impact of TREMFYA (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions and a plenary session
Results from the Phase 2 DAHLIAS study of nipocalimab in SjD show nipocalimab met the primary endpoint with a reduction in ClinESSDAI . . .
* * *
New data for investigational nipocalimab in Sjogren's Disease (SjD) and new research on the impact of TREMFYA (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions and a plenary session
Results from the Phase 2 DAHLIAS study of nipocalimab in SjD show nipocalimab met the primary endpoint with a reduction in ClinESSDAI . . .